


Electronic Supplementary Material – ESM Fig. 2

Standard mean difference in insulin dose (boxes) and pooled estimates (diamonds) calculated by random effects Dersimonian and Laird method. Horizontal bars and diamond widths denote 95% confidence intervals and box sizes indicate relative weight in the analysis.



References

- [40] Gums JG, Curry, Jr., de Oca GM, Skluth HA, Reynolds LR (1992) Treatment of type I diabetes with a combination of glyburide and insulin. *Annals of Pharmacotherapy* 26: 757-762
- [41] Gutniak M, Karlander SG, Efendic S (1987) Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. *Diabetes Care* 10: 545-554
- [43] Kabadi UM, Birkenholz MR (1988) Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. *Archives of Internal Medicine* 148: 1745-1749
- [44] Kabadi UM, McCoy S, Birkenholz M, Kabadi M (1995) More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. *Diabetic medicine: a journal of the British Diabetic Association*: 880-884

- [45] Leblanc H, Thote A, Chatellier G, Passa P (1990) [Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics]. *Diabete et Metabolisme* 16: 93-97
- [47] Lindstrom T, Nystrom FH, Olsson AG, Ottosson AM, Arnqvist HJ (1999) The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. *Diabetic Medicine* 16: 820-826
- [48] Lins PE, Lundblad S, Persson-Trotzig E, Adamson U (1988) Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. *Acta Medica Scandinavica* 223: 171-179
- [49] Riddle M, Hart J, Bingham P, Garrison C, McDaniel P (1992) Combined therapy for obese type 2 diabetes: supertime mixed insulin with daytime sulfonylurea. *American Journal of the Medical Sciences* 303: 151-156
- [50] Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G (1989) Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. *Diabetes Care* 12: 623-629
- [51] Riddle MC, Schneider J (1998) Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. *Diabetes Care* 21: 1052-1057
- [52] Schade DS, Mitchell WJ, Griego G (1987) Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. *JAMA* 257: 2441-2445
- [53] Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L (1988) Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. *Diabetologia* 31: 206-213
- [55] Ryysy L, Yki-Jarvinen H (2001) Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. *Diabetes Care* 24: 549-554